Resultados: 2

    Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV. Policy update 2019

    The World Health Organization’s (WHO’s) strategy for tuberculosis (TB) prevention, care and control for 2015–2035 (known as the End TB Strategy) prioritizes the early diagnosis of TB. This prioritization includes cases of smear-negative disease, which are often associated with coinfection with HIV ...

    The use of lateral flow urine lipoarabinomannan assay (‎LF-LAM)‎ for the diagnosis and screening of active tuberculosis in people living with HIV: policy guidance

    Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have emerged as potential point-of-care tests for tuberculosis (TB). LAM antigen is a lipopolysaccharide present in mycobacterial cell walls, which is released from metabolically active or degenerating bacterial cells ...